Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Avalo Therapeutics (AVTX) EBIT Margin (2016 - 2025)

Avalo Therapeutics filings provide 10 years of EBIT Margin readings, the most recent being 33461.02% for Q4 2025.

  • On a quarterly basis, EBIT Margin fell 2652820.0% to 33461.02% in Q4 2025 year-over-year; TTM through Dec 2025 was 14585.0%, a 95105.0% increase, with the full-year FY2025 number at 123601.69%, down 10806609.0% from a year prior.
  • EBIT Margin hit 33461.02% in Q4 2025 for Avalo Therapeutics, down from 6932.81% in the prior quarter.
  • In the past five years, EBIT Margin ranged from a high of 27.39% in Q3 2022 to a low of 33461.02% in Q4 2025.
  • Median EBIT Margin over the past 5 years was 1588.98% (2023), compared with a mean of 4782.2%.
  • Biggest five-year swings in EBIT Margin: soared 721400bps in 2022 and later plummeted -2652820bps in 2025.
  • Avalo Therapeutics' EBIT Margin stood at 8202.28% in 2021, then surged by 88bps to 988.28% in 2022, then plummeted by -36bps to 1341.16% in 2023, then crashed by -417bps to 6932.81% in 2024, then plummeted by -383bps to 33461.02% in 2025.
  • The last three reported values for EBIT Margin were 33461.02% (Q4 2025), 6932.81% (Q4 2024), and 5165.06% (Q3 2024) per Business Quant data.